UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000034205 |
|---|---|
| Receipt number | R000038991 |
| Scientific Title | An investigator-initiated, multicenter, phase II study to determine the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-Cell lymphoma |
| Date of disclosure of the study information | 2019/01/01 |
| Last modified on | 2023/04/03 11:24:41 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2018/09/20 01:23:25 | ||
| 2 | Update | 2018/09/20 08:44:15 | Interventions/Control_1 |
|
| 3 | Update | 2020/03/16 17:45:04 | Recruitment status Date of IRB Last follow-up date |
|
| 4 | Update | 2020/03/16 18:05:35 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 5 | Update | 2023/04/03 11:24:41 | Recruitment status |
